Coupling mRNA with tRNA and new delivery tech, MPM and OrbiMed help birth new $80M biotech into a slowed down world

Partners at MPM and OrbiMed were hoping David Lockhart could help them with due diligence when they brought him and his team at TranscripTx in to look at a tiny upstart spun out of the University of Texas Southwestern Medical Center in Dallas. Dubbed ReCode Therapeutics, it was developing a lipid nanoparticle (LNP) delivery platform for various genetic medicines, with a lead program in cystic fibrosis backed by the CF Foundation.